Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular
events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …

Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular
complications, which represent the major cause of mortality. Despite effective treatment of …

Hypertension (HTN) is a major modifiable risk factor for cardiovascular disease (CVD)
morbidity and mortality. The left ventricle (LV) is a primary target for HTN end-organ damage …

Despite current established therapy, heart failure (HF) remains a leading cause of
hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to …

SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular
mortality in individuals with type 2 diabetes, although the mechanism (s) of this benefit …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Heart failure (HF) is growing to a modern epidemic and despite advances in therapy, it still
carries an ominous prognosis and a significant socioeconomic burden. 1 Many novel agents …